Core Viewpoint - The biotechnology sector is characterized by high returns and high risks, with successful products potentially surpassing the value of many listed infrastructure and real estate companies [1] Group 1: Company Strategy and Research - The company is currently engaged in multiple cancer vaccine research projects, including the TROP2 cancer vaccine, which has shown significant tumor growth inhibition in preclinical studies [1] - The TROP2 protein is overexpressed in various cancers, including triple-negative breast cancer, lung cancer, and colorectal cancer, with the company's vaccine demonstrating 100% tumor growth inhibition in mouse models [1] - The company estimates that it will take approximately 24-30 months to initiate Phase I/II clinical trials for the TROP2 vaccine [1] Group 2: Asset Management and Financial Strategy - The company considers its health products and agriculture-related businesses as important, generating stable cash flow to support research and development [1] - The company will continue to evaluate strategic options to enhance shareholder value and optimize its business structure, with any significant developments to be disclosed to the market [1] - There are currently no announcements regarding the potential spin-off of the biopharmaceutical division for a Hong Kong listing, and the company is assessing strategic opportunities to improve shareholder value [2] - The company has not announced any plans for fundraising through share placements or convertible bonds to support research and development [2]
长江生命科技(00775)主席李泽钜：生物科技高回报高风险 纯收息买基建或收租股较适合